Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Doxazosin
Drug ID BADD_D00718
Description Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin].[A180661] Because of its long-lasting effects, doxazosin can be administered once a day.[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285]
Indications and Usage For treatment and management of mild to moderate hypertension and urinary obstruction symptoms caused by BPH.
Marketing Status Prescription; Discontinued
ATC Code C02CA04
DrugBank ID DB00590
KEGG ID D07874
MeSH ID D017292
PubChem ID 3157
TTD Drug ID D03MIR
NDC Product Code 0049-2614; 23155-092; 68071-4272; 50090-3927; 42291-259; 70518-2183; 68071-4892; 16729-415; 68382-784; 68788-7149; 70518-1560; 50090-0704; 0049-2040; 70518-1804; 70934-362; 68071-5153; 16729-414; 65427-018; 71610-043; 66267-377; 50090-5773; 70771-1112; 50090-0734; 0904-5523; 16729-213; 60505-0093; 68788-7328; 60505-0094; 68084-862; 43063-739; 59762-2420; 16729-211; 71335-0309; 23155-095; 63629-7891; 68382-785; 59762-2410; 50090-2153; 59762-2480; 71610-628; 68084-836; 71335-0002; 55154-7996; 0049-2410; 70934-921; 71610-153; 50090-0701; 23155-094; 68071-3298; 42291-258; 70771-1113; 0049-2512; 0904-5522; 68084-851; 50090-4000; 50090-4004; 23155-093; 42291-260; 60505-0096; 68382-786; 0904-5524; 50090-5540; 60505-0095; 50090-0706; 50090-3987; 68071-4273; 72189-117; 71610-160; 70934-366; 68382-783; 70771-1114; 70771-1115
Synonyms Doxazosin | Novo-Doxazosin | Novo Doxazosin | Uriduct | Alfamedin | Apo-Doxazosin | Apo Doxazosin | Cardura | Cardular | Zoxan | Carduran | Carduran Neo | Neo, Carduran | Diblocin | Doxa-Puren | Doxa Puren | Doxacor | DoxaUro | Doxagamma | Doxamax | Doxatensa | Doxazomerck | Doxazosin AL | Doxazosin Apogepha | Doxazosin AZU | Doxazosin beta | Doxazosin findusFit | Doxazosin Heumann | Doxazosin Klast | Doxazosin Mesylate | Mesylate, Doxazosin | 1 (4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine | Doxazosin Monohydrochloride | Monohydrochloride, Doxazosin | Doxazosin Stada | Doxazosin Von Ct | Ct, Doxazosin Von | Von Ct, Doxazosin | Doxazosin-ratiopharm | Doxazosin ratiopharm | ratio-Doxazosin | ratio Doxazosin | Doxazosina Ratiopharm | Ratiopharm, Doxazosina | Doxazosin-Wolff | Doxazosin Wolff | Doxazosina Alter | Doxazosina Cinfa | Doxazosina Combino Pharm | Doxazosina Geminis | Doxazosina Normon | Doxazosina Pharmagenus | Doxazosina Ur | Gen-Doxazosin | Gen Doxazosin | Jutalar | MTW-Doxazosin | MTW Doxazosin | Progandol Neo | UK-33274 | UK 33274 | UK33274
Chemical Information
Molecular Formula C23H25N5O5
CAS Registry Number 74191-85-8
SMILES COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nephrolithiasis20.04.01.002--
Nervousness19.06.02.003--Not Available
Neutropenia01.02.03.004--Not Available
Nightmare19.02.03.003--Not Available
Nocturia20.02.03.0010.000485%Not Available
Oedema14.05.06.010; 08.01.07.0060.000727%Not Available
Oesophagitis07.08.05.001--
Oliguria20.01.03.004--Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.0200.001938%Not Available
Otitis media11.01.05.004; 04.05.01.001--
Pain08.01.08.004--
Pain in extremity15.03.04.0100.001212%
Pallor08.01.03.032; 24.03.04.001; 23.03.03.0310.000485%Not Available
Palpitations02.01.02.0030.000969%
Pancreatitis acute07.18.01.0020.001212%Not Available
Pancytopenia01.03.03.0030.000485%Not Available
Paraesthesia17.02.06.0050.001938%
Paresis17.01.04.008--Not Available
Parosmia22.04.03.007; 17.04.04.002--Not Available
Peripheral ischaemia24.04.03.002--
Pharyngitis11.01.13.003; 22.07.03.004; 07.05.07.004--
Photophobia17.17.02.006; 06.01.01.004--
Photosensitivity reaction23.03.09.003--
Platelet count decreased13.01.04.001--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pollakiuria20.02.02.007--
Polymyalgia rheumatica10.04.05.003; 15.06.01.001--Not Available
Polyuria20.02.03.002--Not Available
Presyncope24.06.02.010; 17.02.05.009; 02.01.02.0070.002423%
Priapism21.03.01.005--Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 11 Pages